Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenovaTSE:9341 +0.98%77 EBIT per Share is 円29.58 as of Mar. 2026. GuruFocus rates TSE:9341 with a GF Score™ of 77/100 and a GF Value™ of 円1,971.53 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 685 Medical Devices & Instruments companies, Genova ranks worse than 93.28% on this metric.
Genova's EBIT per Share for the
six
months ended in Mar. 2026 was 円30.82.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円29.58.
During the past 12 months, the average EBIT per Share Growth Rate of Genova was -79.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -38.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Genova's EBIT per Share or its related term are showing as below:
TSE:9341'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.7 Med: 20.1 Max: 39.6
Current: -38.7
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Genova was 39.60% per year. The lowest was -38.70% per year. And the median was 20.10% per year.
TSE:9341's 3-Year EBIT Growth Rate is ranked worse than 93.28% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs TSE:9341: -38.70
Genova's EBIT for the
six
months ended in Mar. 2026 was 円534 Mil.
Genova (TSE:9341) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Genova EBIT per Share Related Terms
Genova EBIT per Share Historical Data
* Premium members only.
The historical data trend for Genova's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円29.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova (TSE:9341) has a EBIT per Share of 円29.58 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genova and its competitors. According to the industry distribution chart, Genova ranks #639 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 93.3%.
Is Genova's EBIT per Share too high?
Genova's current EBIT per Share is 円29.58. Based on the distribution chart, Genova ranks #639 out of 685 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Genova has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genova's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genova ranks #639 out of 685 companies for EBIT per Share. This places Genova in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genova and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genova's current EBIT per Share is 円29.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genova stock overvalued right now?
Based on GuruFocus' analysis, Genova (TSE:9341) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,971.53, compared to a current price of 円616.00 — trading 68.8% below its estimated fair value. The current EBIT per Share is 円29.58. Genova's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genova (TSE:9341), the current EBIT per Share is 円29.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genova (TSE:9341) Overvalued in 2026?
Based on GuruFocus' analysis, Genova stock appears to be undervalued.
The current stock price of 円616.00 is trading 68.8% below its estimated GF Value™ of 円1,971.53.
GuruFocus considers Genova to be Possible Value Trap.
Key valuation signals for TSE:9341:
EBIT per Share: 円29.58
GF Value™: 円1,971.53 vs. price of 円616.00 (68.8% below fair value)
No single metric tells the full story. See the TSE:9341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genova Inc manages operations of the medical information site and sales of automatic reception and payment machines for clinics. The group operates in two reportable segments: Medical Platform Business and the Smart Clinic Project. The majority of its revenue is generated from the Medical Platform Business, which operates an online media site (Medical Dock) that provides preventive information and health knowledge to users (patients) on diseases and symptoms. In addition, it also supports users in finding a family doctor that suits them. The Smart Clinic Business develops and provides services that improve the convenience and efficiency of non-medical procedures at medical institutions.
77GF Score
Get the complete analysis for TSE:9341
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9341 has been successfully added to your 
